Top Markets
Coin of the day
Immunotech Biopharm Ltd Immunotech Biopharm Ltd

Immunotech Biopharm Ltd

6978
Rang in Aktien #27877
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in... Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Aktienkurs
$0.04861197
Marktkapitalisierung
$30.02M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-91.39%
Land
CN
Handel Immunotech Biopharm Ltd (6978)

Kategorie

Dividendenrendite-Verlauf für Immunotech Biopharm Ltd (6978)
Dividendenrendite (TTM) von Immunotech Biopharm Ltd (Aktienkürzel: 6978) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Immunotech Biopharm Ltd (6978) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH